Retatrutide is showing substantial weight-loss results in Phase 3 trials, but it is still investigational and has not been approved by the FDA. A direct Phase 3 trial is comparing Retatrutide with Tirzepatide, so we do not yet know whether Retatrutide should replace Tirzepatide for people who are already doing well on treatment.
How are Retatrutide and Tirzepatide different?
Tirzepatide and Retatrutide both target pathways involved in appetite, metabolism, and blood sugar regulation, but they work differently.
Tirzepatide activates two hormone receptors: GIP and GLP-1. Retatrutide activates those same two pathways and adds glucagon, making it a triple agonist.
That third pathway is one reason Retatrutide has attracted so much attention. Researchers are studying whether activating GIP, GLP-1, and glucagon together can produce greater effects on body weight and metabolic health.
But a different mechanism does not automatically mean a better medication. Tirzepatide is already FDA-approved for chronic weight management, while Retatrutide is still being studied in clinical trials.
How much weight loss has Retatrutide shown?
The weight-loss results are one of the main reasons people are asking whether Retatrutide could eventually replace Tirzepatide.
In the Phase 3 TRIUMPH-1 trial, participants taking the 12 mg dose of Retatrutide lost an average of 28.3% of their body weight after 80 weeks. In TRIUMPH-2, participants with obesity or overweight and type 2 diabetes lost an average of up to 20.8% at 80 weeks. In TRIUMPH-3, participants with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost an average of up to 22.6% at 80 weeks.
Those results are significant, but they should not be treated as a direct comparison with Tirzepatide. The participants, study designs, doses, and health conditions differed between trials.
Is Retatrutide better than Tirzepatide?
We don’t know yet.
The best way to answer a question like this is with a head-to-head clinical trial rather than by comparing results from separate studies.
That’s what the TRIUMPH-5 trial is designed to do. It is a Phase 3, randomized, double-blind study comparing Retatrutide directly with Tirzepatide in adults with obesity. The trial has an estimated enrollment of 800 participants, and its estimated completion date is December 2026.
This kind of comparison matters because two separate weight-loss studies can have very different participants, treatment durations, doses, and starting characteristics.
TRIUMPH-5 is designed to provide a direct comparison of Retatrutide and Tirzepatide, which should help clarify how their weight-loss effects compare.
What if you’re already taking Tirzepatide?
If Tirzepatide is working for you, there is no reason to switch simply because Retatrutide is newer.
You may already be seeing meaningful changes in your weight, appetite, blood sugar, or other health measures. You may also be tolerating your current treatment well.
A newer medication is not automatically a better medication for every person.
If your weight loss has slowed, that’s a different conversation. Weight loss can become slower over time, and a plateau does not necessarily mean your medication has stopped working. Your healthcare provider may consider your current dose, how long you’ve been taking it, changes in appetite and weight, side effects, and other factors before deciding whether your treatment should change.
If your current treatment isn’t working well enough or you’re having difficulty tolerating it, talk with your healthcare provider about your options rather than changing medications on your own.
What could happen if Retatrutide is approved?
If Retatrutide eventually receives FDA approval, it could give healthcare providers another option for treating obesity.
Its three-pathway mechanism and the weight-loss results seen in Phase 3 trials make it an important medication to watch. Lilly has said it plans to submit a Biologics License Application to the FDA in the first quarter of 2027.
But approval would not automatically mean that everyone taking Tirzepatide should switch.
Some people may respond better to one medication. Others may tolerate one better than another. Cost, availability, health conditions, other medications, treatment goals, and individual response could all affect the decision.
There is also more to learn about Retatrutide’s longer-term safety and effectiveness. Phase 3 results are important, but ongoing follow-up and regulatory review will add more information.
For now, the fairest way to describe Retatrutide is as a promising investigational obesity treatment—not a confirmed replacement for Tirzepatide.
Retatrutide vs. Tirzepatide: What we know now
Retatrutide has produced substantial weight loss in Phase 3 clinical trials, but it is still investigational and is not FDA-approved. Tirzepatide, on the other hand, is already an approved treatment for chronic weight management.
The most important unanswered question is whether Retatrutide actually performs better than Tirzepatide when the two are studied directly against each other. TRIUMPH-5 was designed to make that direct comparison, with completion currently expected in December 2026.
Until those results are available and Retatrutide goes through the FDA review process, there is no reason to treat it as a replacement for an existing treatment that is working well for you.
Sources
- Eli Lilly — Retatrutide TRIUMPH-1 Phase 3 results
https://lilly.gcs-web.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial - Eli Lilly — Retatrutide TRIUMPH-2 and TRIUMPH-3 Phase 3 results
https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional - ClinicalTrials.gov — TRIUMPH-5: Retatrutide compared with Tirzepatide
https://clinicaltrials.gov/study/NCT06662383 - U.S. FDA — Zepbound (Tirzepatide) approval for chronic weight management
https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management - Eli Lilly — What to know about Retatrutide
https://www.lilly.com/news/stories/what-to-know-about-retatrutide
Related Articles
This article is general educational information and is not medical advice. Retatrutide remains investigational and is not currently FDA-approved for routine use. It does not replace guidance from your prescriber or pharmacist. Talk with a qualified healthcare professional before starting, stopping, or changing any medication.
